Overview

Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study will characterize the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of AUY922 in adult patients with advanced solid malignancies in Japan.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals